Sharer, 63, joined Amgen in 1992 and served as president until 2000 when he was named chairman and CEO. Under his tenure Amgen grew from $3.6B in revenue with a presence in 17 countries to a company today with revenues approaching $16B and operations in 55 countries.
Bob Bradway, 48, joined Amgen in 2006 as a vice president in operations. He was appointed CFO in 2007, and was named president and chief operating officer in 2010. Prior to joining Amgen, Bradway worked for 19 years with Morgan Stanley. Bradway holds a BA in Biology from Amherst College and an MBA from Harvard University.
Roger Perlmutter, 59, will retire as executive vice president of research and development effective February 12, 2012. Dr. Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013. Dr. Perlmutter joined Amgen in 2000, and during his tenure Amgen has gained the approval for many new drugs, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Sensipar® and Amgen's newest drugs, Prolia® and Xgeva®.
Sean Harper, 49, will assume his new role on February 13, 2012, reporting to Bob Bradway. Dr. Harper will be responsible for Amgen's global research and development functions. Dr. Harper joined Amgen in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety. His current role is senior vice president, global development and he serves as chief medical officer for Amgen. Prior to joining Amgen, Dr. Harper worked for 6 years at Merck Research Laboratories. He attended medical school at UCSF, was board certified in internal medicine and gastroenterology after training at the Massachusetts General Hospital and was a p
Copyright©2010 PR Newswire.
All rights reserved